P635: AN UPDATE OF SAFETY AND EFFICACY RESULTS FROM PHASE 1 STUDY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS

Detalles Bibliográficos
Autores principales: Xu, Wei, Feng, Ru, Wang, LI, Zhu, Huayuan, Zhou, Keshu, Fu, Xiaorui, Jing, Hongmei, Song, Yuqin, Qi, Junyuan, Cui, Guohui, LI, Fei, Wang, Shaoyuan, Zhou, Hui, Qian, Wenbin, Cai, Qingqing, Zhao, Xielan, Guo, Xutao, Wei, Xiaolei, Lin, Ningjing, Xu, Zhongyuan, Wang, Zheng, Xiao, Xiang, Dong, Jiale, Lou, Yejiang, Shen, Yue, Chen, Yi, Chen, Yu, Tan, Fenlai, Anthony, Stephen, LI, Jianyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428909/
http://dx.doi.org/10.1097/01.HS9.0000969444.32459.0c

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428909/
http://dx.doi.org/10.1097/01.HS9.0000969444.32459.0c

Ejemplares similares